MedTrace Logo

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2025-06-04

Study results available
· View outcomes & findings →

Summary

SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.

The purpose of this research study is to see how well SURF-200 works and what side effects there are, and to compare it with vehicle (placebo). The study will involve about 120 study participants at multiple research sites in the United States.

Conditions

Interventions

DRUG

0.02% Betamethasone Sodium Phosphate

topical corticosteroid solution

DRUG

0.04% Betamethasone Sodium Phosphate

topical corticosteroid solution

DRUG

Placebo

topical vehicle solution

Sponsors & Collaborators

  • Surface Ophthalmics, Inc.

    lead INDUSTRY

Principal Investigators

  • Kamran Hosseini, MD, PhD · Surface Ophthalmics, Inc. (formerly Surface Pharmaceuticals, Inc.)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-07
Primary Completion
2022-10-12
Completion
2022-10-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04734210 on ClinicalTrials.gov